ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. - Wikidata - wikimedia - TriplyDB

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

http://www.wikidata.org/entity/Q43684650

about

What is the Need for Prostatic Biomarkers in Prostate Cancer Management?Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients.Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.The role of HOXC6 in prostate cancer development.Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival.RNA biomarkers to facilitate the identification of aggressive prostate cancer ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.Biomarkers for prostate cancer: present challenges and future opportunities.Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?ERG protein expression as a biomarker of prostate cancer.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.Molecular biomarkers to guide precision medicine in localized prostate cancer.ERG expression in prostate cancer: biological relevance and clinical implication.High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment.

P2860

Q26798425-AF0CCDD7-8C87-4249-BE73-9284DC572C70 Q28546607-3C8D487F-1B4A-4A72-9E15-BE302D964C9A Q30573750-FAD861B6-6CB7-4710-8045-9AFFF84E3D8E Q33862890-267570E0-6B74-4B6B-AF2E-DA130D35B531 Q33876961-7BCC2BE7-F9DC-494C-8EF2-D31198D15EF4 Q34036819-9901AE53-A5E7-45EC-A373-2C4769D6047F Q35756663-E010C4C4-6B49-488B-BE36-A517AB10396B Q36021088-5CD0AA52-32B0-4D35-87F4-F6DCA53DCDF2 Q36085659-E30C957E-E458-4180-8F95-D26E310301CF Q36260364-29E44E5A-F426-470E-BF4D-9E9308E6B42C Q36374619-4D64687B-D94D-40D3-855D-405A6AF0C63C Q36848024-0D0EA605-6F79-4432-AB41-6B3513B0BD26 Q36896806-750FA0D0-2C98-487A-9711-0907F9CB0C01 Q36899790-D7BE3209-E58F-4987-BF71-3FA1A6F7A530 Q37100101-86A683A1-CF94-4665-9777-AAB65509FADE Q37156611-073800F9-2C30-4510-AAF0-AB98DBDF2CFC Q37285569-08978EF6-C12A-4FE1-AFFB-B424C1882B83 Q37474443-F9E55367-3F29-4E62-8A39-3547FF9CFA52 Q37520447-D0105E83-4F52-440A-B3E7-BC473CF7F97B Q37727814-60789A83-D0CE-4EFD-87DE-9EE78A274255 Q38151298-FF63DE42-84DB-40B0-A7E8-105426E7A517 Q38165243-0159A9AE-A3CA-473D-AD2E-64CAB31FE629 Q38253055-0A15DDAC-70BF-4545-BFCD-AE4797153305 Q38318517-FE74DE48-D9F5-4F6A-A4D8-371B8B0E1CBB Q38356863-7FB653B1-AFC6-4ACD-A3F9-56ED8B3EE519 Q38391360-721083FC-8EAA-49EE-9C5A-B64F8797E22B Q38399291-462F96AC-8FC9-44F1-BFB3-D9E239CE8AF6 Q38668635-ED227D64-1B8D-40DB-B122-F02F8FAF1F8B Q38681610-C88B0E7E-DA81-4640-B653-80006F49EB13 Q38737037-C0ADF778-1198-4DB9-B62E-A10BC749709D Q38760532-98428105-36CB-4823-BBCB-9B9C72155DC8 Q38774228-BB00980F-D0B5-467B-9A4E-1E33973CC661 Q38909020-2878922A-5106-4B43-A31C-B971ADB782A4 Q39147275-D7A769E7-13D6-476E-A0E6-45E4F9DF7B75 Q39178242-EA49B5BF-A6D6-4821-9656-604B8CDE97F3 Q40322483-74E93676-7063-4E51-8FCB-0CE030069BCD Q40903462-A3905921-3A8D-48E5-AB7D-B4CB3BBD69E7 Q40955215-B62C0CDF-D779-4356-B6F1-FC6F4FCD029B Q41132392-86F20DB9-4082-4C49-B297-76E35F1125BF Q41186635-6BE1CEDD-B415-4ACF-81B5-6A7BD47639B3

P2860

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

http://www.wikidata.org/entity/Q43684650

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@en

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@nl

type

label

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@en

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@nl

prefLabel

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@en

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@nl

P1433

Q43684650-A7AB388C-87BD-4190-A565-3BE3342E4450

P1476

Q43684650-E174816A-C99B-4C79-B2EA-99786308B620

P2093

Q43684650-17CD7803-6DB6-4D71-95B7-36C065F9D6D5

Q43684650-231AFDCD-EBEB-4ED1-9DC8-32FFD2BE1681

Q43684650-2E6B266B-1AF7-4566-8A46-E02A05926E69

Q43684650-312F5542-31A4-4F07-B504-34C1FF5C7F6F

Q43684650-4E37E867-C7BA-41F8-9650-A2585DFC1358

Q43684650-57461CEC-0849-4879-AA7E-28F881D85D85

Q43684650-59BB5872-DDDC-4CEE-8F01-CF6BA580DB00

Q43684650-6427B81C-552F-43EB-B85C-06D6CB88DCDC

Q43684650-88365A2E-9B5C-4201-BAC1-953F284AB69C

P2860

Q43684650-195B5BF1-3C02-4E15-A34E-F480973463F6

Q43684650-26ED6F79-41CB-4290-B984-B9003FD7BD9D

Q43684650-2FB45DDD-8303-4495-976F-5968D9745CC9

Q43684650-338BD910-049D-440B-AEEB-D92EAE4490FD

Q43684650-361E03E1-CBD0-4B6A-B55A-ACBD3E918C2A

Q43684650-472B891C-7C01-417C-849C-9D71B41AF49B

Q43684650-4D074A34-6B9A-45A1-B9F5-87721D6C249F

Q43684650-52DDACB6-01B5-4DDC-A538-008301D51F63

Q43684650-5726295A-24D2-444F-B7F1-6EFCF9C9398E

Q43684650-57285E07-9F5A-4613-B400-C48EEA46E691

P2888

Q43684650-27B4A62D-9BB1-48EB-89BC-CDC0ADA6229C

P304

Q43684650-57DD4802-A01E-4919-936B-2823A4CB9852

P31

Q43684650-F4402E33-B806-450F-81F5-0F43A291B292

P356

Q43684650-829F2EE1-EB73-4090-B288-4C98EB21DED2

P433

Q43684650-30F061B2-C286-42AD-BFCC-2CD025E3D643

P478

Q43684650-B68FE680-80C8-4299-9ADB-CFEF546E412D

P577

Q43684650-FDE2F78E-3836-4C26-94CC-BF9F64652D41

P5875

Q43684650-B50B4A68-7CE3-4187-967A-791E7A193DB8

P6179

Q43684650-8370A518-7CD4-4DDA-9ACA-BEBD2A2CD363

P698

Q43684650-3A812782-4589-43C7-826A-6951A1CA4045

P921

Q43684650-1003D460-EF80-49E2-B421-17D9FB092E96

P356

MODPATHOL.2011.176

P1433

Modern Pathology

P1476

ERG immunohistochemistry is no ...... tatectomy for prostate cancer.

@en

P2093

A Marije Hoogland

http://www.w3.org/2001/XMLSchema#string

Fritz H Schröder

http://www.w3.org/2001/XMLSchema#string

Geert Jlh van Leenders

http://www.w3.org/2001/XMLSchema#string

Guido Jenster

http://www.w3.org/2001/XMLSchema#string

Jan Trapman

http://www.w3.org/2001/XMLSchema#string

Mark F Wildhagen

http://www.w3.org/2001/XMLSchema#string

Monique J Roobol

http://www.w3.org/2001/XMLSchema#string

Theo van der Kwast

http://www.w3.org/2001/XMLSchema#string

Wytske M van Weerden

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Role of the TMPRSS2-ERG gene fusion in prostate cancer

Screening and prostate-cancer mortality in a randomized European study

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Antibody-based detection of ERG rearrangement-positive prostate cancer

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.

P2888

modpathol.2011.176

P304

471-479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2011.176

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51795631

http://www.w3.org/2001/XMLSchema#string

P6179

1032668134

http://www.w3.org/2001/XMLSchema#string

P698

22080055

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry